Risedronate Sodium Capsules

Risedronate sodium can bind to hydroxyapatite in bones and inhibit bone resorption. At the cellular level, this product inhibits osteoclasts. Osteoclasts are usually present on the surface of bones, but do not have obvious resorption activity. Histomorphometric measurements of rats, dogs, and piglets showed that this product can reduce bone turnover (activation frequency, that is, the rate at which bone tissue remodeling sites are activated) and resorption of bone remodeling sites.

This product is a film-coated tablet, which appears white or off-white after removing the coating.

This product is used to treat and prevent osteoporosis in postmenopausal women.

Oral administration. It should be taken in an upright position at least 30 minutes before meals, with a glass (about 200ml) of water. It is not advisable to stay in bed within 30 minutes after taking the medicine. The dosage is once a day, 5mg (one tablet) each time.

1. Digestive system can cause upper gastrointestinal disorders, manifested as dysphagia, esophagitis, esophageal or gastric ulcers, and can also cause diarrhea, abdominal pain, nausea, constipation, etc. 2. Others such as flu-like syndrome, headache, dizziness, rash, joint pain, etc.

1. This product is contraindicated for those who are known to be allergic to it; 2. This product is contraindicated for those with hypocalcemia; 3. This product is contraindicated for those who have difficulty standing or sitting within 30 minutes; 4. This product has serious adverse reactions on breastfeeding infants, and breastfeeding women should stop taking the drug or stop breastfeeding.

Precautions for children: The safety and effectiveness of the drug for children has not been established. Precautions for pregnancy and lactation: The safety and effectiveness of the drug for pregnant women has not been established. This product should be used during pregnancy only when the disease itself is more harmful to the mother and child and there is no other safer drug alternative. This product has serious adverse reactions to breastfeeding infants. Lactating women should stop taking the drug or stop breastfeeding. Precautions for the elderly: Clinical trial data show that there is no difference in safety and effectiveness between the elderly and young people when taking this product, but it does not rule out that the elderly are highly sensitive to this product.

There are no reports of specific drug interactions with this product. This product is not metabolized, nor does it induce or inhibit liver cytochrome P450. Calcium/Antacids Taking this product with calcium, antacids, and oral preparations containing divalent cations will affect its absorption.

Keep sealed.

5mg (calculated as C7H10NO7P2Na)

24 months

Jiangsu Chiatai Qingjiang Pharmaceutical Co., Ltd.

• Founded in:

  2001-02-28

• Address:

  No. 9, Hantai North Road, Huai'an City, Jiangsu Province

• Tax NO.:

  91320800134784998M

• Registered Funds:

  180 million yuan

• Website:

  Log in to view

• Email:

  Log in to view